Development of treatment and clinical results in childhood
acute myeloid leukemia in the Czech Republic

J 2013

Development of treatment and clinical results in childhood acute myeloid leukemia in the Czech Republic

ŠRÁMKOVÁ, Lucie; Jaroslav ŠTĚRBA; Hana HRSTKOVÁ; Vladimír MIHÁL; Bohumír BLAŽEK et. al.

Základní údaje

Originální název

Development of treatment and clinical results in childhood acute myeloid leukemia in the Czech Republic

Autoři

Vydání

Memo - Magazine of European Medical Oncology, Springer, 2013, 1865-5041

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Rakousko

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14110/13:00070797

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1007/s12254-012-0059-3

UT WoS

000219619500012

Klíčová slova anglicky

Acute myeloid leukemia; Children; AMLBFMA93; AML-BFM 98; AML-BFM 2004; Czech Republic

Příznaky

Recenzováno

Změněno: 18. 4. 2014 09:53, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Purpose Treatment of childhood acute myeloid leukemia (AML) was unified in the year 1993 according to acute myeloid leukemia-Berlin–Frankfurt–Munster (AML-BFM) protocols in the Czech Republic. We evaluated data on clinical and therapeutic results in children with AML treated in three subsequent trials, comparing two periods, June 1993 to February 2004 (AML-BFM 93 and 98) vs. March 2004 to December 2009 (AML-BFM 2004 trial).Patients and methods Data of 182 eligible patients were analyzed, 125 in AML-BFM 93 and 98 trials, and 57 in AML-BFM 2004 trial enrolled prior to December 2009. Down syndrome patients were excluded from analysis. Results In studies AML-BFM 93 and 98, 79.2 % of 125 patients achieved complete remission (CR), 19 patients (15.2 %) suffered from early death, 7 (5.6 %) were nonresponders, 33 (33.3 %) relapsed, 12 (12.1 %) died in CR, and 2 patients (2.0 %) developed secondary malignancy. The estimated probability of event-free survival (pEFS) at 5 years was 41.6 %, the overall survival (OS) at 5 years was 46.4 %. In AML-BFM 2004 trial, 93 % of 57 patients attained CR, 3 patients (5.2 %) suffered from early death, 1 (1.8 %) was nonresponder, 16 (30.2 %) relapsed, 2 (3.8 %) died in CR, and 2 patients (3.5 %) developed secondary malignancy. The estimated pEFS at 5 years was 56.1 %, 5-years overall survival (5y-OS) was 73.7 %. Conclusion Gradual improvement of CR rate and OS together with decreasing incidence of toxic deaths in AML patients were achieved because of gain of experience with very intensive modern treatment centralized in a limited number of institutions.

Citovat

ŠRÁMKOVÁ, Lucie; Jaroslav ŠTĚRBA; Hana HRSTKOVÁ; Vladimír MIHÁL; Bohumír BLAŽEK; Pavel TIMR; Zdena ČERNÁ; Daniela PROCHÁZKOVÁ; Jiří HAK; Petr SEDLÁČEK; Iveta JANOTOVÁ; Elena VODIČKOVÁ; Zuzana ZEMANOVÁ; Marie JAROŠOVÁ; Alexandra OLTOVÁ; Kateřina ZDRÁHALOVÁ; Ondrej HRUSAK; Ester MEJSTRIKOVA; Jiří SCHWARZ; Jan ZUNA; Jan TRKA a Jan STARÝ. Development of treatment and clinical results in childhood acute myeloid leukemia in the Czech Republic. Memo - Magazine of European Medical Oncology. Springer, 2013, roč. 6, č. 1, s. 41-45. ISSN 1865-5041. Dostupné z: https://doi.org/10.1007/s12254-012-0059-3.

@article{1138873,
   author = {Šrámková, Lucie and Štěrba, Jaroslav and Hrstková, Hana and Mihál, Vladimír and Blažek, Bohumír and Timr, Pavel and Černá, Zdena and Procházková, Daniela and Hak, Jiří and Sedláček, Petr and Janotová, Iveta and Vodičková, Elena and Zemanová, Zuzana and Jarošová, Marie and Oltová, Alexandra and Zdráhalová, Kateřina and Hrusak, Ondrej and Mejstrikova, Ester and Schwarz, Jiří and Zuna, Jan and Trka, Jan and Starý, Jan},
   article_number = {1},
   doi = {https://doi.org/10.1007/s12254-012-0059-3},
   keywords = {Acute myeloid leukemia; Children; AMLBFMA93; AML-BFM 98; AML-BFM 2004; Czech Republic},
   language = {eng},
   issn = {1865-5041},
   journal = {Memo - Magazine of European Medical Oncology},
   title = {Development of treatment and clinical results in childhood acute myeloid leukemia in the Czech Republic},
   volume = {6},
   year = {2013}
}

TY  - JOUR
ID  - 1138873
AU  - Šrámková, Lucie - Štěrba, Jaroslav - Hrstková, Hana - Mihál, Vladimír - Blažek, Bohumír - Timr, Pavel - Černá, Zdena - Procházková, Daniela - Hak, Jiří - Sedláček, Petr - Janotová, Iveta - Vodičková, Elena - Zemanová, Zuzana - Jarošová, Marie - Oltová, Alexandra - Zdráhalová, Kateřina - Hrusak, Ondrej - Mejstrikova, Ester - Schwarz, Jiří - Zuna, Jan - Trka, Jan - Starý, Jan
PY  - 2013
TI  - Development of treatment and clinical results in childhood acute myeloid leukemia in the Czech Republic
JF  - Memo - Magazine of European Medical Oncology
VL  - 6
IS  - 1
SP  - 41-45
EP  - 41-45
PB  - Springer
SN  - 18655041
KW  - Acute myeloid leukemia
KW  - Children
KW  - AMLBFMA93
KW  - AML-BFM 98
KW  - AML-BFM 2004
KW  - Czech Republic
N2  - Purpose Treatment of childhood acute myeloid leukemia (AML) was unified in the year 1993 according to acute myeloid leukemia-Berlin–Frankfurt–Munster (AML-BFM) protocols in the Czech Republic. We evaluated data on clinical and therapeutic results in children with AML treated in three subsequent trials, comparing two periods, June 1993 to February 2004 (AML-BFM 93 and 98) vs. March 2004 to December 2009 (AML-BFM 2004 trial).Patients and methods Data of 182 eligible patients were analyzed, 125 in AML-BFM 93 and 98 trials, and 57 in AML-BFM 2004 trial enrolled prior to December 2009. Down syndrome patients were excluded from analysis. Results In studies AML-BFM 93 and 98, 79.2 % of 125 patients achieved complete remission (CR), 19 patients (15.2 %) suffered from early death, 7 (5.6 %) were nonresponders, 33 (33.3 %) relapsed, 12 (12.1 %) died in CR, and 2 patients (2.0 %) developed secondary malignancy. The estimated probability of event-free survival (pEFS) at 5 years was 41.6 %, the overall survival (OS) at 5 years was 46.4 %. In AML-BFM 2004 trial, 93 % of 57 patients attained CR, 3 patients (5.2 %) suffered from early death, 1 (1.8 %) was nonresponder, 16 (30.2 %) relapsed, 2 (3.8 %) died in CR, and 2 patients (3.5 %) developed secondary malignancy. The estimated pEFS at 5 years was 56.1 %, 5-years overall survival (5y-OS) was 73.7 %. Conclusion Gradual improvement of CR rate and OS together with decreasing incidence of toxic deaths in AML patients were achieved because of gain of experience with very intensive modern treatment centralized in a limited number of institutions.
ER  -

ŠRÁMKOVÁ, Lucie; Jaroslav ŠTĚRBA; Hana HRSTKOVÁ; Vladimír MIHÁL; Bohumír BLAŽEK; Pavel TIMR; Zdena ČERNÁ; Daniela PROCHÁZKOVÁ; Jiří HAK; Petr SEDLÁČEK; Iveta JANOTOVÁ; Elena VODIČKOVÁ; Zuzana ZEMANOVÁ; Marie JAROŠOVÁ; Alexandra OLTOVÁ; Kateřina ZDRÁHALOVÁ; Ondrej HRUSAK; Ester MEJSTRIKOVA; Jiří SCHWARZ; Jan ZUNA; Jan TRKA a Jan STARÝ. Development of treatment and clinical results in childhood acute myeloid leukemia in the Czech Republic. \textit{Memo - Magazine of European Medical Oncology}. Springer, 2013, roč.~6, č.~1, s.~41-45. ISSN~1865-5041. Dostupné z: https://doi.org/10.1007/s12254-012-0059-3.

Přehled o publikaci